Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. SPCX
3. MU
4. ACN
5. IBM
6. SPY
7. NVDA
8. PRIM
9. PFE
10. TSLA

Go back to Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
(NASDAQ: RYTM) Delayed: 105.40 +4.01 (3.96%)
Previous Close $101.39    52 Week High $ 
Open $101.00    52 Week Low $ 
Day High $106.13    P/E N/A 
Day Low $99.49    EPS $ 
Volume 586,512